• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

13C-aminopyrine demethylation is decreased in cirrhotic patients with normal biochemical markers.

作者信息

Afolabi Paul, Wright Mark, Wootton Steve A, Jackson Alan A

机构信息

a National Institute for Health Research Biomedical Research Centre (Nutrition), Southampton Centre for Biomedical Research, Southampton General Hospital , Southampton , UK.

出版信息

Isotopes Environ Health Stud. 2013;49(3):346-56. doi: 10.1080/10256016.2013.803098. Epub 2013 Jun 25.

DOI:10.1080/10256016.2013.803098
PMID:23799253
Abstract

This study determined the rates of (13)C-aminopyrine metabolism in patients with varying degrees of liver cirrhosis as defined by clinical scores. Twenty-five cirrhotic patients and 18 healthy subjects underwent a (13)C-aminopyrine breath test. The cumulative per cent dose recovery (cPDR) of (13)C on breath expressed as a percentage of the administered dose at 2 h was significantly lower in cirrhotic patients than in healthy subjects (median: 1.7% versus 9.0%; p<.0001). Significant inverse associations between cPDR at 2 h and the model for end-stage liver disease score, Child-Pugh score, international normalised ratio and bilirubin (all p<.05), but not alanine aminotransferase or alkaline phosphatase were observed in the cirrhotic patients. Taking each biochemical marker independently, cirrhotic patients with normal biochemistry had a significantly lower cPDR at 2 h than healthy subjects (all p<.05). Differences in (13)C-aminopyrine metabolism were evident in cirrhotic patients with less severe disease and may mark hepatic dysfunction when conventional biochemical markers appear unchanged.

摘要

相似文献

1
13C-aminopyrine demethylation is decreased in cirrhotic patients with normal biochemical markers.
Isotopes Environ Health Stud. 2013;49(3):346-56. doi: 10.1080/10256016.2013.803098. Epub 2013 Jun 25.
2
Noninvasive diagnosis and prognosis of liver cirrhosis: a comparison of biological scores, elastometry, and metabolic liver function tests.非侵入性诊断和肝硬化预后:生物标志物评分、弹性成像和代谢肝功能检测的比较。
Eur J Gastroenterol Hepatol. 2010 May;22(5):532-40. doi: 10.1097/MEG.0b013e3283343f58.
3
The relationship between aminopyrine breath test and severity of liver disease in cirrhosis.氨基比林呼气试验与肝硬化患者肝脏疾病严重程度的关系。
Am J Gastroenterol. 1981 Aug;76(2):110-3.
4
13CO2 excretion in breath of normal subjects and cirrhotic patients after 13C-aminopyrine oral load. Comparison with MEGX test in functional differentiation between chronic hepatitis and liver cirrhosis.正常受试者和肝硬化患者口服13C-氨基比林后呼出气体中13CO2的排泄。与MEGX试验在慢性肝炎和肝硬化功能鉴别中的比较。
Hepatogastroenterology. 2000 Jan-Feb;47(31):234-8.
5
13C-aminopyrine breath test to evaluate severity of disease in patients with chronic hepatitis C virus infection.
Aliment Pharmacol Ther. 2002 Apr;16(4):717-25. doi: 10.1046/j.1365-2036.2002.01200.x.
6
A comparison of the reproducibility of the parameters of the ¹³C-aminopyrine breath test for the assessment of hepatic function.用于评估肝功能的¹³C-氨基比林呼气试验参数的可重复性比较。
Isotopes Environ Health Stud. 2011 Sep;47(3):390-9. doi: 10.1080/10256016.2011.595791. Epub 2011 Jul 11.
7
Impaired hepatic mitochondrial oxidation using the 13C-methionine breath test in patients with macrovesicular steatosis and patients with cirrhosis.使用13C-蛋氨酸呼气试验评估大泡性脂肪变性患者和肝硬化患者的肝脏线粒体氧化受损情况。
Med Sci Monit. 2003 Jan;9(1):CR6-11.
8
A simple method for routine determination of the metabolic liver capacity: the aminopyrine breath test.一种用于常规测定肝脏代谢能力的简单方法:氨基比林呼气试验。
Int J Clin Pharmacol Ther Toxicol. 1985 Apr;23(4):190-6.
9
Prognostic Value of Metabolic Liver Function Tests: a Study on 711 Cirrhotic Patients.代谢肝功能试验的预后价值:711 例肝硬化患者的研究。
J Gastrointestin Liver Dis. 2016 Sep;25(3):337-43. doi: 10.15403/jgld.2014.1121.253.lft.
10
¹³C-methacetin breath test in the evaluation of disease severity in patients with liver cirrhosis.¹³C-美沙西汀呼气试验在评估肝硬化患者疾病严重程度中的应用
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2013 Dec;157(4):392-400. doi: 10.5507/bp.2012.114. Epub 2013 Mar 22.

引用本文的文献

1
European guideline on indications, performance and clinical impact of C-breath tests in adult and pediatric patients: An EAGEN, ESNM, and ESPGHAN consensus, supported by EPC.欧洲成人和儿科患者 C 呼吸试验适应证、性能和临床影响指南:EAGEN、ESNM 和 ESPGHAN 共识,得到 EPC 的支持。
United European Gastroenterol J. 2021 Jun;9(5):598-625. doi: 10.1002/ueg2.12099. Epub 2021 Jun 14.
2
Enzymatic liver function capacity correlates with disease severity of patients with liver cirrhosis: a study with the LiMAx test.酶促肝功能能力与肝硬化患者的疾病严重程度相关:一项使用LiMAx检测的研究。
Dig Dis Sci. 2014 Dec;59(12):2983-91. doi: 10.1007/s10620-014-3250-z. Epub 2014 Jul 4.